Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 381, Issue 17, 2019, Pages 1609-1620

  Solomon, S D ^a   McMurray, J J V ^b   Anand, I S ^e   Ge, J ^g   Lam, C S P ^h   Maggioni, A P ⁱ   Martinez, F ^k   Packer, M ^l   Pfeffer, M A ^a   Pieske, B ^m   Redfield, M M ^f   Rouleau, J L ^o   Van Veldhuisen, D J ^ab   Zannad, F ^q   Zile, M R ^r   Desai, A S ^a   Claggett, B ^a   Jhund, P S ^b   Boytsov, S A ^s   Comin Colet, J ^t   Cleland, J ^c,d   Dungen H D ^n,p   Goncalvesova, E ^u   Katova, T ^v   Kerr Saraiva, J F ^w   Lelonek, M ^x   Merkely, B ^y   Senni, M ^j   Shah, S J ^z   Zhou, J ^g   Rizkala, A R ^aa   Gong, J ^aa   Shi, V C ^aa   Lefkowitz, M P ^aa   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MAYO CLINIC   (United States)

^g FUDAN UNIVERSITY   (China)

^h DEPARTMENT OF CARDIOLOGY   (Singapore)

ⁱ ANMCO RESEARCH CENTER   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^l BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^m DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o MONTREAL HEART INSTITUTE   (Canada)

^p UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^q UNIVERSITÉ DE LORRAINE   (France)

^r MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^s INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^t HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^u National Cardiovascular Institute   (Slovakia)

^v National Cardiology Hospital   (Bulgaria)

^w UNIVERSITY OF SÃO PAULO   (Brazil)

^x MEDICAL UNIVERSITY OF LODZ   (Poland)

^y SEMMELWEIS UNIVERSITY   (Hungary)

^z NORTHWESTERN UNIVERSITY   (United States)

^aa NOVARTIS PHARMA AG   (Switzerland)

^ab NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; KIDNEY FUNCTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; QUALITY OF LIFE; SEX FACTOR; SINGLE BLIND PROCEDURE;

AGED; AMINOBUTYRATES; ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; NEPRILYSIN; QUALITY OF LIFE; SEX FACTORS; SINGLE-BLIND METHOD; STROKE VOLUME; TETRAZOLES; VALSARTAN;

EID: 85074240365     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1908655     Document Type: Article

References (23)

1. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med 2017;376:897.
2. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015;131:550-9.
3. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure — abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350: 1953-9.
4. Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63:447-56.
5. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
6. Massie BM, Carson PE, McMurray JJV, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.
7. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45.
8. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92.
9. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
10. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95.
11. Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial. JACC Heart Fail 2017;5:471-82.
12. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35:1245-55.
13. Lin DW, Wei LJ, Yang I, Ying Z. Semi-parametric regression for the mean and rate functions of recurrent events. J R Stat Soc B 2000;62:711-30.
14. Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and survival times. Appl Stat 2006;55:31-9.
15. Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015;131:269-79.
16. Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015;132:402-14.
17. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455-62.
18. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230-9.
19. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35.
20. Abdul-Rahim AH, Shen L, Rush CJ, Jhund PS, Lees KR, McMurray JJV. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail 2018; 20:1139-45.
21. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113-22.
22. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 2014;16:1049-55.
23. Lam CS, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation 2017; 135:1279-80.